-Viktor Magdolen Researcher Activity Profile

Research Author Detailed Information 

Viktor Magdolen Publication Rate By Year

Viktor Magdolen has published 2 paper(s) in 2003, 1 paper(s) in 2006, 4 paper(s) in 2007, 5 paper(s) in 2008, for a total of 12 research publications in total.

Viktor V Magdolen Author Information

LAST NAME: magdolen

FIRST NAME: Viktor

INITIALS: v

AFFILIATION:

Papers

Viktor Magdolen's Publication Record

1. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. Year Published: 2006
Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D-81675 Munich, Germany, and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
2. Structural basis of the zinc inhibition of human tissue kallikrein 5. Year Published: 2007
3. Structural basis of the zinc inhibition of human tissue kallikrein 5. Year Published: 2007
4. Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7. Year Published: 2007
5. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Year Published: 2007
6. The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Year Published: 2008
Department of Obstetrics and Gynecology, Technical University of Munich, Ismaninger Str. 22, D-81675 Munich, Germany.
7. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: Comparison to antigen quantification by ELISA. Year Published: 2008
Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D-81675 Munich, Germany.
8. The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Year Published: 2008
Department of Obstetrics and Gynecology, Technical University of Munich, Ismaninger Str. 22, D-81675 Munich, Germany.
9. The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction. Year Published: 2003
Klinische Forschergruppe, Frauenklinik, Technische Universität München, 81675 Munich, Germany.
10. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Year Published: 2003
Klinische Forschergruppe der Frauenklinik der TU München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675 Munich, Germany.
11. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Year Published: 2008
Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, D-81675 Munich, Germany.
12. The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. Year Published: 2008
Department of Obstetrics and Gynecology, Technical University of Munich, Ismaninger Str. 22, D-81675 Munich, Germany.